Inhibition of DXR in the MEP pathway with lipophilic <i>N</i>-alkoxyaryl FR900098 analogs-Reference-Cited by-同舟云学术

Inhibition of DXR in the MEP pathway with lipophilic N-alkoxyaryl FR900098 analogs

Published:2024 Issue:7 Volume:15 Page:2422-2439
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Bague Darean¹,Wang Ruiqin¹,Hodge Dana²^ORCID,Mikati Marwa O.³^ORCID,Roma Jose S.⁴,Boshoff Helena I.⁴^ORCID,Dailey Allyson L.⁵,Girma Misgina⁵,Couch Robin D.⁵^ORCID,Odom John Audrey R.²³^ORCID,Dowd Cynthia S.¹^ORCID

Affiliation:

1. Department of Chemistry, George Washington University, Washington, D.C. 20052, USA

2. Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA

3. Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 63110, USA

4. Tuberculosis Research Section, LCIM, NIAID/NIH, Bethesda, MD 20892, USA

5. Department of Chemistry and Biochemistry, George Mason University, Fairfax, VA 22030, USA

Abstract

Isoprene biosynthesis is a point of vulnerability for many pathogens. Building on prior work, we report a novel set of potent compounds that display selectivity for P. falciparum over M. tuberculosis, and act on-target intracellularly.

Funder

National Institute of Allergy and Infectious Diseases

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MD/D3MD00642E

Reference60 articles.

1. World Malaria Report 2022 , World Health Organization , Geneva , 2022 , https://www.who.int/publications/i/item/9789240064898

2. Global Tuberculosis Report 2022 , World Health Organization , Geneva , 2022 , https://www.who.int/teams/global-tuberculosis-programme/tb-reports

3. Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains

4. The Expanding Diversity of Mycobacterium tuberculosis Drug Targets

5. Genomic Deoxyxylulose Phosphate Reductoisomerase (DXR) Mutations Conferring Resistance to the Antimalarial Drug Fosmidomycin in E. coli